$ABL
Abacus Life, Inc. Stock $abl

$abl Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000181428723000030 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$23.70M	$21.12M	$0.00
YoY Change
Cost Of Revenue	$1.662M	$3.365M	$1.755M
YoY Change		91.75%
Gross Profit	$22.03M	$17.76M	$9.753M
YoY Change		82.06%
Gross Profit Margin	92.98%	84.07%
Selling, General & Admin	$17.16M	$11.54M	$74.72K
YoY Change		15348.27%
% of Gross Profit	77.87%	65.01%	0.77%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.710M	$1.695M	$1.071K
YoY Change		158149.58%
% of Gross Profit	7.76%	9.55%	0.01%
Operating Expenses	$20.92M	$11.46M	$8.900M
YoY Change	866.84%	28.71%	1473.72%
Operating Profit	$1.116M	$6.300M	$10.67M
YoY Change		-40.93%
Interest Expense	-$2.759M	$2.679M	$2.600M
YoY Change	203.67%	3.03%	-77.05%
% of Operating Profit	-247.18%	42.53%	24.38%
Other Income/Expense, Net	-$3.406M	-$3.539M	$2.600M
YoY Change	-763.66%	-236.08%	-77.05%
Pretax Income	-$7.135M	$2.760M	-$6.300M
YoY Change	178.85%	-143.81%	-158.53%
Income Tax	-$769.9K	$1.710M	$47.04K
% Of Pretax Income		61.97%
Net Earnings	-$6.222M	$903.4K	-$6.347M
YoY Change	144.36%	-114.23%	-158.97%
Net Earnings / Revenue	-26.26%	4.28%
Basic Earnings Per Share		$0.01	$0.20
Diluted Earnings Per Share	-$0.10	$0.01	-$255.8K
COMMON SHARES
Basic Shares Outstanding	63.35M shares	62.96M shares	50.37M shares
Diluted Shares Outstanding		63.35M shares	50.37M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.84M	$36.60M	$1.675M
YoY Change	32060.75%	2085.26%	40.31%
Cash & Equivalents	$25.59M	$36.65M	$1.675M
Short-Term Investments	$2.253M
Other Short-Term Assets	$699.1K	$1.000M	$308.3K
YoY Change	977.08%	224.39%	120.59%
Inventory
Prepaid Expenses			$308.3K
Receivables	$3.236M	$1.900M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$31.78M	$39.52M	$1.983M
YoY Change	20876.75%	1892.74%	48.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$400.7K	$261.9K
YoY Change	2052.44%
Goodwill	$140.3M	$140.3M
YoY Change
Intangibles	$29.62M	$31.22M
YoY Change
Long-Term Investments	$126.8M	$91.80M	$98.26M
YoY Change	27.84%	-6.57%	-71.52%
Other Assets	$999.0K	$1.000M
YoY Change	12.14%
Total Long-Term Assets	$300.0M	$264.8M	$98.26M
YoY Change	202.4%	169.47%	-71.52%
TOTAL ASSETS
Total Short-Term Assets	$31.78M	$39.52M	$1.983M
Total Long-Term Assets	$300.0M	$264.8M	$98.26M
Total Assets	$331.8M	$304.3M	$100.2M
YoY Change	233.92%	203.56%	-71.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$0.00	$2.000K	$4.924M
YoY Change	-100.0%	-99.96%	228.29%
Accrued Expenses	$4.354M	$636.8K	$7.940M
YoY Change	-52.81%	-91.98%	4680.78%
Deferred Revenue	$507.0K	$348.8K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$13.03M
YoY Change
Total Short-Term Liabilities	$23.33M	$5.458M	$12.93M
YoY Change	24.2%	-57.79%	-31.95%
LONG-TERM LIABILITIES
Long-Term Debt	$126.8M	$118.8M	$0.00
YoY Change
Other Long-Term Liabilities	$8.440M	$3.400M	$12.08M
YoY Change		-71.84%	0.0%
Total Long-Term Liabilities	$135.2M	$122.2M	$12.08M
YoY Change		912.01%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.33M	$5.458M	$12.93M
Total Long-Term Liabilities	$135.2M	$122.2M	$12.08M
Total Liabilities	$167.8M	$138.2M	$29.67M
YoY Change	793.24%	365.9%	-4.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$34.73M	-$28.50M	-$27.51M
YoY Change	88.58%	3.63%
Common Stock			$24.14K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$163.9M	$165.8M	-$27.48M
YoY Change
Total Liabilities & Shareholders Equity	$331.8M	$304.3M	$100.2M
YoY Change	233.92%	203.56%	-71.06%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$6.222M	$903.4K	-$6.347M
YoY Change	144.36%	-114.23%	-158.97%
Depreciation, Depletion And Amortization	$1.710M	$1.695M	$1.071K
YoY Change		158149.58%
Cash From Operating Activities	-$13.34M	-$12.82M	-$1.350M
YoY Change	2031.12%	849.73%	230.65%
INVESTING ACTIVITIES
Capital Expenditures	$89.67K	$100.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$238.8K	$9.730M	$247.1M
YoY Change	-75.18%	-96.06%
Cash From Investing Activities	-$328.5K	$9.630M	$247.1M
YoY Change	-65.86%	-96.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.617M	19.22M	-244.7M
YoY Change		-107.86%	-16410.86%
NET CHANGE
Cash From Operating Activities	-13.34M	-12.82M	-1.350M
Cash From Investing Activities	-328.5K	9.630M	247.1M
Cash From Financing Activities	2.617M	19.22M	-244.7M
Net Change In Cash	-11.05M	16.03M	1.112M
YoY Change	595.98%	1341.13%	1.88%
FREE CASH FLOW
Cash From Operating Activities	-$13.34M	-$12.82M	-$1.350M
Capital Expenditures	$89.67K	$100.0K
Free Cash Flow	-$13.43M	-$12.92M
YoY Change	2045.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	63349823	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30052823	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	1754894	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	9752854	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1704154	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.43
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.43
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36649190	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	961427	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	116646	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	39518757	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	33282927	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	261882	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18617	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31217917	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	usd
CY2023Q3	us-gaap	Goodwill Goodwill	140287000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	171295	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	77011	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	4116499	usd
CY2022Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	8716111	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	83585374	usd
CY2022Q4	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	13809352	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	1000000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	1000000	usd
CY2023Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1650000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1300000	usd
CY2023Q3	us-gaap	Other Receivable After Allowance For Credit Loss Noncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent	998469	usd
CY2022Q4	us-gaap	Other Receivable After Allowance For Credit Loss Noncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent	0	usd
CY2023Q3	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	1494744	usd
CY2022Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	890829	usd
CY2023Q3	us-gaap	Assets Assets	304301937	usd
CY2022Q4	us-gaap	Assets Assets	59094847	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	636788	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	0	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	40014	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	173799	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	48127	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	348836	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2023Q3	abl	Accrued Transaction Costs Current AccruedTransactionCostsCurrent	0	usd
CY2022Q4	abl	Accrued Transaction Costs Current AccruedTransactionCostsCurrent	908256	usd
CY2023Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	80573	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5457675	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1302409	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29268	usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	10558687	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1363820	usd
CY2023Q3	abl	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	3382000	usd
CY2022Q4	abl	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	0	usd
CY2023Q3	us-gaap	Liabilities Liabilities	138212190	usd
CY2022Q4	us-gaap	Liabilities Liabilities	30945150	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	194197741	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	704963	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28503752	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	25487323	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	100175	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1052836	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	289248	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	899538	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	166089747	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28149697	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	304301937	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59094847	usd
CY2023Q3	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	1817764	usd
CY2022Q3	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	10629978	usd
	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	18473597	usd
	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	24610444	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	17108380	usd
CY2022Q3	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	495525	usd
	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	21447464	usd
	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	3801031	usd
CY2022Q3	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	11125503	usd
	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	39921061	usd
	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	28411475	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	3364957	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4827907	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3840969	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	17755973	usd
	us-gaap	Gross Profit GrossProfit	37877997	usd
	us-gaap	Gross Profit GrossProfit	25943079	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14905	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3116999	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1664403	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4583632	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4583632	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9838951	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	59816	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11113382	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	706523	usd
CY2023Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	2088797	usd
CY2022Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	1235032	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	491356	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1301821	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1694853	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1071	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1696994	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3211	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	11455961	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	-912394	usd
	us-gaap	Operating Expenses OperatingExpenses	15745884	usd
	us-gaap	Operating Expenses OperatingExpenses	2816439	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	6300012	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	10665248	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	22132113	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	23126640	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	943400	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	943400	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	2679237	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	0	usd
	us-gaap	Interest Expense InterestExpense	3620695	usd
	us-gaap	Interest Expense InterestExpense	0	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	63826	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	71283	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20086	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	42289	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1565	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-199958	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3538725	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	42289	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4494377	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-199958	usd
CY2023Q3	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	2761287	usd
CY2022Q3	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	10707537	usd
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	17637736	usd
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	22926682	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1710315	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	352081	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2238419	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	648887	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	1050972	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	10355456	usd
	us-gaap	Profit Loss ProfitLoss	15399317	usd
	us-gaap	Profit Loss ProfitLoss	22277795	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	147611	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	363452	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-339692	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	770093	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	903361	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	9992004	usd
	us-gaap	Net Income Loss NetIncomeLoss	15739009	usd
	us-gaap	Net Income Loss NetIncomeLoss	21507702	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.20
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.20
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.43
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63349823	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63349823	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50369350	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50369350	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54632826	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54632826	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50369350	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50369350	shares
CY2022Q3	us-gaap	Profit Loss ProfitLoss	10355456	usd
	us-gaap	Profit Loss ProfitLoss	15399317	usd
	us-gaap	Profit Loss ProfitLoss	22277795	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	-1016034	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	-523083	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	-1248010	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	1494476	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	34938	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	9832373	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	14151307	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	23772271	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-91292	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	124677	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-635041	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1136586	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	126230	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	9707696	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	14786348	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	22635685	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	12306791	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	22139164	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	160498915	usd
CY2023Q3	abl	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	0	usd
CY2023Q3	abl	Adjustments To Additional Paid In Capital Increase From Spac Trust Proceeds AdjustmentsToAdditionalPaidInCapitalIncreaseFromSPACTrustProceeds	972262	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4583632	usd
CY2023Q3	abl	Noncontrolling Interest Increase From Transfer Of Noncontrolling Interest NoncontrollingInterestIncreaseFromTransferOfNoncontrollingInterest	0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1016034	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	1050972	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	166089747	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	766893	usd
	us-gaap	Dividends Dividends	2400000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1494476	usd
	us-gaap	Profit Loss ProfitLoss	22277795	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	22139164	usd
	us-gaap	Dividends Dividends	34451607	usd
	abl	Stockholders Equity Deferred Transaction Costs StockholdersEquityDeferredTransactionCosts	10841551	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	960900	usd
	abl	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	-2796225	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	165361332	usd
	abl	Adjustments To Additional Paid In Capital Increase From Spac Trust Proceeds AdjustmentsToAdditionalPaidInCapitalIncreaseFromSPACTrustProceeds	972262	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4583632	usd
	abl	Noncontrolling Interest Increase From Transfer Of Noncontrolling Interest NoncontrollingInterestIncreaseFromTransferOfNoncontrollingInterest	0	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1248010	usd
	us-gaap	Profit Loss ProfitLoss	15399317	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	166089747	usd
	us-gaap	Profit Loss ProfitLoss	15399317	usd
	us-gaap	Profit Loss ProfitLoss	22277795	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1696994	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3211	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4583632	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	133211	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	491356	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1301821	usd
	us-gaap	Life Settlement Contracts Fair Value Method Unrealized Gain Loss LifeSettlementContractsFairValueMethodUnrealizedGainLoss	14259665	usd
	us-gaap	Life Settlement Contracts Fair Value Method Unrealized Gain Loss LifeSettlementContractsFairValueMethodUnrealizedGainLoss	3957809	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-309865	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	859519	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1743079	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	648887	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	1064130	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
	abl	Operating Lease Right Of Use Asset Noncash Income Expense OperatingLeaseRightOfUseAssetNoncashIncomeExpense	721	usd
	abl	Operating Lease Right Of Use Asset Noncash Income Expense OperatingLeaseRightOfUseAssetNoncashIncomeExpense	-192	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	929020	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-29199	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	364931	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	325294	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1920015	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	634409	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-38014	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	44103901	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	112388	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	usd
	abl	Increase Decrease In Accrued Transaction Costs IncreaseDecreaseInAccruedTransactionCosts	-908256	usd
	abl	Increase Decrease In Accrued Transaction Costs IncreaseDecreaseInAccruedTransactionCosts	0	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-632381	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	3089077	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1352878	usd
	abl	Life Settlement Contract Purchased Fair Value Method LifeSettlementContractPurchasedFairValueMethod	55516357	usd
	abl	Life Settlement Contract Purchased Fair Value Method LifeSettlementContractPurchasedFairValueMethod	7105000	usd
	abl	Life Settlement Contract Purchased Investment Method LifeSettlementContractPurchasedInvestmentMethod	5601493	usd
	abl	Life Settlement Contract Purchased Investment Method LifeSettlementContractPurchasedInvestmentMethod	61876742	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-51176074	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6395331	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	350000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	250000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	96721	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	abl	Proceeds Due From Payments Due To Affiliates ProceedsDueFromPaymentsDueToAffiliates	3016158	usd
	abl	Proceeds Due From Payments Due To Affiliates ProceedsDueFromPaymentsDueToAffiliates	-1682664	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2569437	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1932664	usd
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	442283	usd
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	2500000	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	87478232	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	12900291	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	943400	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	10841551	usd
	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	0	usd
	abl	Proceeds Received From Spac Trust ProceedsReceivedFromSPACTrust	972262	usd
	abl	Proceeds Received From Spac Trust ProceedsReceivedFromSPACTrust	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55203004	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12069661	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6596367	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3741666	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30052823	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102421	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36649190	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3844087	usd
	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Organization and Merger</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Abacus Life, Inc. (the “Company”) was formerly known as East Resources Acquisition Company ("ERES”), a blank check company incorporated in Delaware on May 22, 2020. Abacus Life, Inc. conducts its business through its wholly-owned, consolidated subsidiaries, primarily Abacus Settlements, LLC (“Abacus Settlements”, or “Abacus”) and Longevity Market Assets, LLC (“LMA”), which are Delaware limited liability companies (collectively, the “Companies”). On June 30, 2023, (the “Closing Date”), ERES, LMA and Abacus Settlements, LLC consummated the combining of the Companies as contemplated by the Merger Agreement dated as of August 30, 2022 (as amended on October 14, 2022 and April 20, 2023) with LMA Merger Sub, LLC, a wholly owned subsidiary of ERES (“LMA Merger Sub”), Abacus Merger Sub, LLC, a wholly owned subsidiary of ERES (“Abacus Merger Sub”), LMA and Abacus (together with LMA, the “Legacy Companies”). Pursuant to the Merger Agreement, on June 30, 2023, (i) LMA Merger Sub merged with and into LMA, with LMA surviving such merger (the “LMA Merger”) and (ii) Abacus Merger Sub merged with and into Abacus, with Abacus surviving such merger (the “Abacus Merger” and, together with the LMA Merger, the “Mergers” and, along with the other transactions contemplated by the Merger Agreement, the “Business Combination”) and the Legacy Companies became direct wholly owned subsidiaries of Abacus and ERES changed its name to Abacus Life, Inc. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated assets, liabilities and statements of operations and comprehensive income prior to the Business Combination are those of legacy LMA. The shares of common stock and corresponding capital amounts and income per share, prior to the Business Combination, have been retroactively restated based on share reflecting the exchange ratio established in the Business Combination. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The equity structure has been recast in all comparative periods up to the Closing Date to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to legacy LMA’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and income per share related to legacy LMA common stock prior to the Business Combination have been retroactively recast as shares reflecting the exchange ratio of 0.8 established in the Business Combination.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Activity</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company, through its LMA subsidiary, is a provider of services pertaining to life insurance settlements and offers policy servicing to owners and purchasers of life settlement assets, as well as consulting, valuation, and actuarial services. The Company is also engaged in buying and selling of life settlement policies in which it uses its own capital, and purchases life settlement contracts with the intent to either hold to maturity to receive the associated death claim payout or to sell to another purchaser of life settlement contracts for a gain on the sale.</span></div>The Company, through its Abacus subsidiary, also is an originator of outstanding life insurance policies as a licensed life settlement provider on behalf of investors (“Financing Entities”). Abacus locates and screens policies for eligibility as a commercially desirable life settlement, including verifying that the policy is in force, obtaining consents and disclosures, and submitting cases for life expectancy estimates, also known, collectively, as origination services. When the sale of a policy is completed, this is deemed “settled” and the policy is then referred to as either a “life settlement” in which the insured’s life expectancy is greater than two years or “viatical settlement,” in which the insured’s life expectancy is less than two years. The Company is not an insurance company, and therefore the Company does not underwrite insurable risks for its own account.
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	abl	Number Of Providers Involved In Option Agreement NumberOfProvidersInvolvedInOptionAgreement	2	provider
CY2021Q4	abl	Number Of Unaffiliated Investors Involved In Variable Interest Entity Ownership NumberOfUnaffiliatedInvestorsInvolvedInVariableInterestEntityOwnership	3	investor
CY2021Q4	abl	Number Of Unaffiliated Investors Involved In Variable Interest Entity Ownership NumberOfUnaffiliatedInvestorsInvolvedInVariableInterestEntityOwnership	3	investor
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The preparation of U.S. GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, disclosure of contingent assets and liabilities at the date of financial statements, and the reports amounts of revenue and expenses during the reporting periods. Company’s estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from the estimates. Estimates are used when accounting for revenue recognition and related costs, purchase price allocation, the selection of useful lives of property and equipment, valuation of other receivables, valuation of life settlement policies, valuation of other investments and available-for-sale securities, valuation of long-term debt, impairment testing, income taxes, and legal reserves.</span>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentrations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, accounts receivable, and available-for-sale securities. The Company maintains its cash in bank deposit accounts with high-quality financial institutions, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on its cash and cash equivalents. For accounts receivable, the Company is exposed to credit risk in the event of nonpayment by customers to the extent of the amounts recorded on the accompanying condensed consolidated balance sheets. The Company extends different levels of credit to its customers and maintains allowance for doubtful accounts based upon the expected collectability of accounts receivable. The Company’s procedures for determining this allowance includes evaluating individual customer receivables, considering a customer’s financial condition, monitoring credit history and current economic conditions, and using historical experience applied to an aging of accounts.</span>
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2023Q3	abl	Life Settlement Contracts Number Of Contracts LifeSettlementContractsNumberOfContracts	240	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	228	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	12	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	303605030	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	83585374	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	37300000	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	4116499	usd
CY2022Q4	abl	Life Settlement Contracts Number Of Contracts LifeSettlementContractsNumberOfContracts	53	insurance_contract
CY2022Q4	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	35	insurance_contract
CY2022Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	18	insurance_contract
CY2022Q4	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	40092154	usd
CY2022Q4	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	13809352	usd
CY2022Q4	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	42330000	usd
CY2022Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	8716111	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Remainder Of Fiscal Year LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInRemainderOfFiscalYear	0	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Remainder Of Fiscal Year LifeSettlementContractsFairValueMethodFaceValueMaturingInRemainderOfFiscalYear	0	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Remainder Of Fiscal Year LifeSettlementContractsFairValueMaturingInRemainderOfFiscalYear	0	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Next Twelve Months LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInNextTwelveMonths	8	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Next Twelve Months LifeSettlementContractsFairValueMethodFaceValueMaturingInNextTwelveMonths	10639000	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Next Twelve Months LifeSettlementContractsFairValueMaturingInNextTwelveMonths	8018927	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Two LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearTwo	13	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Two LifeSettlementContractsFairValueMethodFaceValueMaturingInYearTwo	26725000	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Two LifeSettlementContractsFairValueMaturingInYearTwo	8912395	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Three LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearThree	36	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Three LifeSettlementContractsFairValueMethodFaceValueMaturingInYearThree	69378938	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Three LifeSettlementContractsFairValueMaturingInYearThree	28670576	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Four LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearFour	26	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Four LifeSettlementContractsFairValueMethodFaceValueMaturingInYearFour	22391998	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Four LifeSettlementContractsFairValueMaturingInYearFour	8115654	usd
CY2023Q3	abl	Life Settlement Contract Fair Value Method Number Of Contracts Maturity After Year Four LifeSettlementContractFairValueMethodNumberOfContractsMaturityAfterYearFour	145	insurance_contract
CY2023Q3	abl	Life Settlement Contract Fair Value Method Face Value Maturity After Year Four LifeSettlementContractFairValueMethodFaceValueMaturityAfterYearFour	174470094	usd
CY2023Q3	abl	Life Settlement Contract Fair Value Maturity After Year Four LifeSettlementContractFairValueMaturityAfterYearFour	29867822	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	228	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	303605030	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	83585374	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Remainder Of Fiscal Year LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInRemainderOfFiscalYear	0	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Remainder Of Fiscal Year LifeSettlementContractsInvestmentMethodFaceValueMaturingInRemainderOfFiscalYear	0	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Remainder Of Fiscal Year LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInRemainderOfFiscalYear	0	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInNextTwelveMonths	1	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodFaceValueMaturingInNextTwelveMonths	500000	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInNextTwelveMonths	329714	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Two LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearTwo	2	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Two LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearTwo	1500000	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Two LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearTwo	437775	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Three LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearThree	1	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Three LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearThree	8000000	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Three LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearThree	82869	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Four LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFour	2	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Four LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFour	500000	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Four LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearFour	320110	usd
CY2023Q3	abl	Life Settlement Contract Investment Method Number Of Contracts Maturity After Year Four LifeSettlementContractInvestmentMethodNumberOfContractsMaturityAfterYearFour	6	insurance_contract
CY2023Q3	abl	Life Settlement Contract Investment Method Face Value Maturity After Year Four LifeSettlementContractInvestmentMethodFaceValueMaturityAfterYearFour	26800000	usd
CY2023Q3	abl	Life Settlement Contract Investment Method Amount Maturity After Year Four LifeSettlementContractInvestmentMethodAmountMaturityAfterYearFour	2946031	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	12	insurance_contract
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	37300000	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	4116499	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Remainder Of Fiscal Year LifeSettlementContractsInvestmentMethodPremiumsToBePaidInRemainderOfFiscalYear	59184	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Next Twelve Months LifeSettlementContractsInvestmentMethodPremiumsToBePaidInNextTwelveMonths	411445	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Two LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearTwo	403224	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Three LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearThree	97789	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Four LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFour	71775	usd
CY2023Q3	abl	Life Settlement Contract Investment Method Premium To Be Paid After Year Four LifeSettlementContractInvestmentMethodPremiumToBePaidAfterYearFour	654558	usd
CY2023Q3	us-gaap	Life Settlement Contracts Investment Method Five Year Disclosure Premiums To Be Paid LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid	1697975	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1682083	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	6728333	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	276792	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25346	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14911	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6729	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	261882	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18617	usd
CY2023Q3	us-gaap	Depreciation Depreciation	12770	usd
CY2022Q3	us-gaap	Depreciation Depreciation	1070	usd
	us-gaap	Depreciation Depreciation	14911	usd
	us-gaap	Depreciation Depreciation	3211	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	32900000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29300000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1682083	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27617917	usd
CY2023Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	32900000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1682083	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31217917	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1682083	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1682083	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	5328333	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3911667	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3895000	usd
CY2023Q3	abl	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	6072501	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27617917	usd
CY2021Q4	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	250000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	250000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Weighted Average Yield DebtSecuritiesAvailableForSaleWeightedAverageYield	0.06
CY2021Q4	abl	Debt Securities Available For Sale Equity Financing Threshold In Which Shares Convert DebtSecuritiesAvailableForSaleEquityFinancingThresholdInWhichSharesConvert	1000000	usd
CY2022Q4	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	500000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Weighted Average Yield DebtSecuritiesAvailableForSaleWeightedAverageYield	0.08
CY2022Q4	abl	Debt Securities Available For Sale Equity Financing Threshold In Which Shares Convert DebtSecuritiesAvailableForSaleEquityFinancingThresholdInWhichSharesConvert	5000000	usd
CY2023Q3	abl	Debt Securities Available For Sale Equity Financing Threshold In Which Shares Convert DebtSecuritiesAvailableForSaleEquityFinancingThresholdInWhichSharesConvert	1000000	usd
CY2022Q4	abl	Debt Securities Available For Sale Equity Financing Threshold In Which Shares Convert DebtSecuritiesAvailableForSaleEquityFinancingThresholdInWhichSharesConvert	1000000	usd
CY2023Q3	abl	Number Of Entities In Which Equity Securities Without Readily Determinable Fair Value Are Held NumberOfEntitiesInWhichEquitySecuritiesWithoutReadilyDeterminableFairValueAreHeld	2	entity
	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
CY2023Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
CY2022Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
CY2023Q3	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2023Q3	us-gaap	Revenues Revenues	21120930	usd
CY2023Q3	us-gaap	Revenues Revenues	21120930	usd
CY2022Q3	us-gaap	Revenues Revenues	11507748	usd
CY2022Q3	us-gaap	Revenues Revenues	11507748	usd
	us-gaap	Revenues Revenues	42705904	usd
	us-gaap	Revenues Revenues	42705904	usd
	us-gaap	Revenues Revenues	29784048	usd
	us-gaap	Revenues Revenues	29784048	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	17755973	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	9752854	usd
	us-gaap	Gross Profit GrossProfit	37877997	usd
	us-gaap	Gross Profit GrossProfit	25943079	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1704154	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14905	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3116999	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1664403	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4583632	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4583632	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9838951	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	59816	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11113382	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	706523	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1694853	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1071	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1696994	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3211	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20086	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	42289	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1565	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-199958	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	943400	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	943400	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	2679237	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	0	usd
	us-gaap	Interest Expense InterestExpense	3620695	usd
	us-gaap	Interest Expense InterestExpense	0	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	63826	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	71283	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	usd
CY2023Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	2088797	usd
CY2022Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	1235032	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-309865	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	859519	usd
CY2023Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-306800	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-246846	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	491356	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1301821	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1710315	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	352081	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2238419	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	648887	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	147611	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	363452	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-339692	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	770093	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	903361	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	9992004	usd
	us-gaap	Net Income Loss NetIncomeLoss	15739009	usd
	us-gaap	Net Income Loss NetIncomeLoss	21507702	usd
CY2023Q3	abl	Sensitivity Analysis Of Fair Value Life Settlement Contracts Fair Value Impact Of2 Percent Positive Change In Discount Rate SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate	78288612	usd
	abl	Sensitivity Analysis Of Fair Value Change In Life Settlement Contracts Fair Value Impact Of2 Percent Positive Change In Discount Rate SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate	-5296762	usd
CY2023Q3	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	83585374	usd
CY2023Q3	abl	Sensitivity Analysis Of Fair Value Life Settlement Contracts Fair Value Impact Of2 Percent Adverse Change In Discount Rate SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate	89102871	usd
	abl	Sensitivity Analysis Of Fair Value Change In Life Settlement Contracts Fair Value Impact Of2 Percent Adverse Change In Discount Rate SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate	5517497	usd
CY2023Q3	abl	Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets	-760457	usd
CY2023Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome	-777131	usd
CY2023Q3	abl	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Equity Attributable To Noncontrolling Interest FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEquityAttributableToNoncontrollingInterest	238902	usd
CY2023Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	2088797	usd
	abl	Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets	-1945461	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome	952661	usd
	abl	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Equity Attributable To Noncontrolling Interest FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEquityAttributableToNoncontrollingInterest	295348	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-309865	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	28249653	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	88618714	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-309865	usd
	us-gaap	Fair Value Option Credit Risk Gains Losses On Assets FairValueOptionCreditRiskGainsLossesOnAssets	-1635596	usd
	abl	Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets	-1945461	usd
CY2023Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	118813828	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	250000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	250000	usd
CY2022Q4	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	500000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1000000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1000000	usd
CY2023Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1650000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1300000	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	abl	Number Of Votes Per Common Share NumberOfVotesPerCommonShare	1	vote
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63349823	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63349823	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50369350	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50369350	shares
	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2023Q3	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	61586	usd
CY2022Q3	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4511	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	86901	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	12559	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1710315	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	352081	usd
CY2023Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.619
CY2022Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.033
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2238419	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	648887	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.127
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.028
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M29D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0342
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0336
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	171295	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	77011	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	173799	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	48127	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29268	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	173799	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	77395	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	69904	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	12471	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	94846	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	36313	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	20540	usd
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	1221	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	29465	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	2444	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	90444	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	13692	usd
	us-gaap	Lease Cost LeaseCost	124311	usd
	us-gaap	Lease Cost LeaseCost	38757	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	96891	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	36121	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	117527	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	118058	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	0	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	usd
CY2023Q3	abl	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	0	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	235585	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	61786	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	173799	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	903361	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	9992004	usd
	us-gaap	Net Income Loss NetIncomeLoss	15739009	usd
	us-gaap	Net Income Loss NetIncomeLoss	21507702	usd
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63349823	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63349823	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50369350	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50369350	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54632826	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54632826	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50369350	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50369350	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.20
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.20
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29

Files In Submission

Name	View Source	Status
0001814287-23-000030-index-headers.html	Edgar Link	pending
0001814287-23-000030-index.html	Edgar Link	pending
0001814287-23-000030.txt	Edgar Link	pending
0001814287-23-000030-xbrl.zip	Edgar Link	pending
abacuslifeincfs093023311.htm	Edgar Link	pending
abacuslifeincfs093023312.htm	Edgar Link	pending
abacuslifeincfs093023321.htm	Edgar Link	pending
abacuslifeincfs093023322.htm	Edgar Link	pending
abl-20230930.htm	Edgar Link	pending
abl-20230930.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
abl-20230930_lab.xml	Edgar Link	unprocessable
abl-20230930_cal.xml	Edgar Link	unprocessable
abl-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abl-20230930_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
abl-20230930_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABL
Abacus Life, Inc. Stock $abl

2023 Q4 Form 10-Q Financial Statement

#000181428723000030 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABL Abacus Life, Inc. Stock $abl

2023 Q4 Form 10-Q Financial Statement

#000181428723000030 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABL
Abacus Life, Inc. Stock $abl